Addressing Gaps in Knowledge of Best Practices in Metastatic Triple-Negative Breast Cancer

Of all women diagnosed with cancer in the United States, 30% have breast cancer, which is the second-leading cause of cancer death in this group. Many women have benefitted from regular screening as well as earlier and improved treatment; however, 6% of women present with metastatic disease, and 30% with no initial lymph node involvement will develop metastatic disease. Women with metastatic breast cancer have a poorer prognosis than the overall population of breast cancer patients, and research...
Continue reading

Sacituzumab Govitecan for TNBC: An Interview With Sara Tolaney, MD, MPH

The FDA recently granted approval to sacituzumab govitecan-hziy (Trodelvy™, Immunomedics, Inc) for patients with metastatic triple-negative breast cancer (TNBC) who have received at least two prior therapies. Approval was based on a clinical trial (NCT01631552) that enrolled 108 patients with metastatic TNBC. In an interview with i3 Health, Sara Tolaney, MD, MPH, one of the study authors, provides insights on treating TNBC and the significance of the sacituzumab govitecan approval. What are the ...
Continue reading

Breast Cancer: Liquid Biopsies Better Than Tumor Biopsies

Patients with hormone receptor (HR)-positive metastatic breast cancer are typically treated with endocrine therapy. However, patients with mutations in the genes PIK3CA and ESR1 usually develop resistance to endocrine therapy. To discover ways to effectively identify PIK3CA and ESR1 mutations in patients with HR-positive metastatic breast cancer and predict treatment outcomes, researchers at Stanford University evaluated the efficacy of using liquid biopsies compared with solid tumor biopsies to...
Continue reading

Subscribe

Get the latest updates delivered to your inbox!

Follow Us

Copyright © 2021 Oncology Data Advisor. All rights reserved.